Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s footer revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a change in the site build rather than any study details.
    Difference
    0.1%
    Check dated 2026-04-25T16:56:28.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A new release version v3.5.2 was added and the previous v3.5.0 was removed.
    Difference
    0.1%
    Check dated 2026-04-18T12:56:51.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Added a citation to iRECIST guidelines in the references and removed the corresponding erratum note.
    Difference
    0.1%
    Check dated 2026-04-04T05:08:02.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added to the page. Revision: v3.4.3 was removed from the page.
    Difference
    0.1%
    Check dated 2026-03-20T19:51:12.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Updated the iRECIST guideline reference to the Lancet Oncol 2017 guidelines (version 3.4.3), replacing the older 3.4.2 citation.
    Difference
    0.1%
    Check dated 2026-03-06T18:17:42.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Minor version update from v3.4.1 to v3.4.2; study details and page layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T13:40:44.000Z thumbnail image

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.